RecruitingNot ApplicableNCT06116292

Impact of the Implementation of a Telemedicine Program on Patients Diagnosed with Asthma


Sponsor

Hospital Universitari de Bellvitge

Enrollment

108 participants

Start Date

Jan 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Introduction: Asthma is one of the most common chronic respiratory diseases worldwide. Despite the extensive knowledge of the condition and available therapeutic options, severe asthmatic patients have poor disease control in 50% of cases. Objective: To assess the impact of implementing a mobile application (ESTOI) in patients diagnosed with asthma on disease control, treatment adherence, and perceived quality of life. Methodology: A 52-week randomized clinical trial involving asthma patients receiving care at a highly specialized hospital in Spain. A total of 108 patients will be included and divided into two groups. The intervention group will receive more comprehensive monitoring than usual, including access to the ESTOI application. The Asthma Control Test (ACT) questionnaire will be used as the primary assessment variable. Other variables to be studied include the Inhaler Adherence Test (TAI), the number of exacerbations, peak expiratory flow, exhaled nitric oxide examination, hospital anxiety and depression scale, asthma quality of life questionnaire, forced spirometry parameters (FVC, FEV1, and reversibility), and analytical parameters (eosinophilia and IgE).


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Age ≥18 years with a diagnosis of asthma based on GEMA 5.2 2022.
  • Patients seen in the pulmonology service of the center.
  • Patients who have not previously received asthma education.
  • Capable of giving signed informed consent.

Exclusion Criteria5

  • Patient who does not have a mobile device with Android or IOS system.
  • Lack of minimum technological knowledge for the use of the application (ESTOI).
  • People who are participating or have participated in a clinical trial in the last 6 months.
  • Patients diagnosed with other respiratory diseases except for obstructive sleep apnea (OSA), Asthma-COPD overlap syndrome (ACOS).
  • Patients with palliative or severe chronic illnesses that limit their life expectancy.

Interventions

DEVICEThe mobile application ESTOI for Asthmatic patients

The mobile application ESTOI have various sections that can be managed and customized by the researchers to meet each patient's needs: 1. SYMPTOM CONTROL, it will record the ACT, TAI, the number of exacerbations, weight, and, depending on the case, symptom control for comorbidities. 2. RECOMMENDATIONS, it will provide patients with information needed to understand their condition, how to control it, and what to do in case of worsening symptoms. 3. YOUR TREATMENT, it will display personalized and update information about the patient's current asthma medication, including dosages and frequencies. There will be explanatory videos on how to administer the therapy and includes an action plan. 4. PEAK FLOW, the patient can record measurements using a Peak Flow Meter at home. 5. NUTRITIONAL PLAN, it will provide a daily dietary guide to enable individuals to adapt these tools and recommendations to their specific needs. 6. MESSAGING, it is a bidirectional contact area.


Locations(1)

Bellvitge University Hospital

Barcelona, Barcelona, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06116292


Related Trials